June 30, 2025

Use of Adjuvant Aspirin Reduces the Risk of Recurrence in PI3K-Mutated Colorectal Cancer

In a groundbreaking study presented at the 2025 ASCO Gastrointestinal Cancers Symposium, Dr. Anna Martling highlights the substantial reduction in colorectal cancer recurrence risk with adjuvant daily aspirin in patients with PI3K pathway alterations.

The ASCO Post

June 30, 2025

Five Major Advances in Radiotherapy for Anal and Rectal Cancer Presented at ESTRO 2025

Rectal cancer is one of the most common cancers in Europe, with over 125,000 people diagnosed annually. Treatment traditionally involves surgery to remove the tumor—a major operation that can permanen...

The ASCO Post

June 30, 2025

Benefits of Walnut Consumption: Curbing Inflammation, Colorectal Cancer Risk

Researchers have uncovered that eating walnuts may improve systemic inflammation and reduce the risk for colorectal cancer.

The ASCO Post

June 30, 2025

DDW 2025: 20-Year Screening Program Drives Down Colorectal Cancer Cases, Deaths

A 20-year initiative that offered flexible options for colorectal cancer screening at a major integrated health system doubled colorectal cancer screening rates, cut cancer incidence by a third, halve...

The ASCO Post

June 30, 2025

Impact of Empirical Dietary Inflammatory Pattern on Survival Outcomes in Patients With Stage III Colon Cancer

Results from a large, prospective study show that eating a less inflammatory diet may reduce the risk of death for patients with stage III colon cancer.

The ASCO Post

June 30, 2025

Order of CRC Diagnosis May Influence Survival in Patients With Multiple Malignancies

The order of colorectal cancer diagnosis seems to have a significant impact on outcomes in patients with multiple primary malignancies, according to the results of a study of SEER Program data.

The ASCO Post

June 30, 2025

Predictive Biomarker Under Study in Colorectal Cancer

Researchers have uncovered a biomarker that may determine response to cell therapy and survival in patients with colorectal cancer.

The ASCO Post

June 30, 2025

Updated Results Confirm Benefit of Combination Regimen in BRAFV600E–Mutated Metastatic Colorectal Cancer

Patients with previously untreated BRAF V600E–mutated metastatic colorectal cancer who receive the BRAF inhibitor encorafenib and the EGFR inhibitor cetuximab plus mFOLFOX6 (modified leucovorin, fluor...

The ASCO Post

June 27, 2025

In Case You Missed It: Abstracts on Novel Therapies in Gastrointestinal Cancers

Four noteworthy studies from the 2025 ASCO Gastrointestinal Cancers Symposium, each shedding new light on emerging therapeutic approaches for patients with advanced gastric, hepatocellular, and colore...

The ASCO Post